Day: February 9, 2021

Basel, Switzerland, February 09, 2021Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a milestone payment to Basilea of USD 10 million.Basilea is entitled to receive milestone payments upon Pfizer’s cumulative Cresemba sales in Pfizer’s licensed territories exceeding certain thresholds. Pfizer is currently commercializing Cresemba in many European countries, including France, Germany, Italy, Spain and the U.K, as well as in a number of countries in the Asia Pacific region. Under the agreement, sales milestones totaling USD 12 million were triggered in 2019 and regulatory and commercial milestones totaling around USD 6 million were triggered in 2020.David Veitch, Chief Executive Officer of Basilea, said: “We are...

Basel, 09. Februar 2021Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die von Pfizer mit dem Antimykotikum Cresemba® (Isavuconazol) in Europa und Israel erzielten Umsätze die Schwelle überschritten haben, durch die eine Meilensteinzahlung an Basilea in Höhe von USD 10 Mio. ausgelöst wurde.Basilea hat Anspruch auf Meilensteinzahlungen, wenn die kumulierten Cresemba-Umsätze von Pfizer in deren Lizenzgebieten bestimmte Schwellenwerte überschreiten. Pfizer vermarktet Cresemba derzeit in vielen europäischen Ländern, darunter Frankreich, Deutschland, Italien, Spanien und Grossbritannien sowie in einer Reihe von Ländern im asiatisch-pazifischen Raum. Im Rahmen der Vereinbarung wurden in 2019 Umsatzmeilensteine in Höhe von insgesamt USD 12 Mio. ausgelöst sowie in 2020 regulatorische und kommerzielle Meilensteine in Höhe von rund...

On exclusion of shares from the regulated marketJSC “Grindeks” hereby informs that according to the decision of the unscheduled General Meeting of JSC “Grindeks” that took place on 12.11.2020 a decision to delist the shares of JSC “Grindeks” from the stock exchange, observing the provisions of Paragraph 7 of Section 77 of the Financial Instruments Market Law, as well as Provision 12.1 of Nasdaq Riga rule On Listing and Trading in Financial Instruments on Exchange Regulated Markets  JSC “Grindeks” submitted to the organizer of the regulated market to the joint stock company “Nasdaq Riga” an application for exclusion of JSC “Grindeks” from the regulated market on 09.02.2021.Further information:Laila KlavinaHead of the Communications Department, JSC “Grindeks” Phones:...

Par akciju izslēgšanu no regulētā tirgusAr šo AS “Grindeks” informē, ka saskaņā ar 12.11.2020 AS “Grindeks” ārkārtas akcionāru sapulcē nolemto par AS “Grindeks” akciju izslēgšanu no biržas, ievērojot Finanšu instrumentu tirgus likuma 77. panta septītās daļā noteikto, kā arī Nasdaq Riga noteikumu “Par finanšu instrumentu iekļaušanu un tirdzniecību biržas regulētajos tirgos” 12.1. punktu, AS “Grindeks” ir 09.02.2021 iesniegusi regulētā tirgus organizētājam akciju sabiedrībai “Nasdaq Riga” iesniegumu par AS “Grindeks” izslēgšanu no regulētā tirgus.Kontakti:Laila Kļaviņa, AS “Grindeks” Komunikācijas departamenta vadītājaTel.: 67083370, 29256012fakss: 67083505E-pasts: laila.klavina@grindeks.lvwww.grindeks.lv

PRESS RELEASENyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)Mont-Saint-Guibert, Belgium – 9th February 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces that the Company has received approval by the Food and Drug Administration (FDA) for the Magnetic Resonance Imaging (MRI) conditional labeling for the Genio® neurostimulation-based OSA therapy, currently being evaluated in the DREAM pivotal IDE study.This revised labeling ensures that patients who receive the Genio® system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved...

COMMUNIQUÉ DE PRESSENyxoah reçoit l’autorisation de la FDA pour la compatibilité avec les scanners IRM corps entier 1,5 T et 3 T de son système Genio® qui permet de traiter le Syndrome d’Apnée Obstructive du Sommeil (SAOS)Mont-Saint-Guibert, Belgique – 9 février 2021 – Nyxoah SA (Euronext : NYXH) (« Nyxoah » ou « la Société »), opère dans le secteur des technologies de la santé et se concentre sur le développement et la commercialisation de solutions et de services visant à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). Elle annonce aujourd’hui que son système Genio® pour le traitement du SAOS basé sur la neurostimulation, actuellement évalué par l’étude pivot IDE DREAM, a reçu l’approbation par la Food and Drug Administration (FDA) pour le marquage conditionnel relatif à l’Imagerie par Résonance Magnétique (IRM).Ce...